SGEF Double Nickase Plasmid (h): sc-409874-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SGEF Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- SGEF Double Nickase Plasmid (h) and SGEF Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ARHGEF26. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SGEF Antibody (E-5): sc-514048
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SGEF Double Nickase Plasmid (h) | sc-409874-NIC | 20 µg | $410.00 |
ARHGEF26 encodes SGEF, a Dbl-family Rho guanine nucleotide exchange factor that activates Rho GTPases, with prominent roles in RhoG-driven cytoskeletal remodeling and membrane trafficking. Through regulation of actin dynamics, SGEF influences cell adhesion, migration, and endocytic processes, linking upstream signaling inputs to coordinated changes in cell shape and polarity. ARHGEF26-dependent Rho signaling interfaces with pathways controlling inflammatory cell responses and epithelial barrier behavior, making it relevant to studies of immune signaling, host–pathogen interactions, and tissue remodeling. Dysregulated Rho GTPase activation and altered cytoskeletal control are commonly associated with oncogenic phenotypes and invasive cell behavior, positioning SGEF as a mechanistic node for dissecting motility-associated disease biology.
SGEF Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ARHGEF26 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ARHGEF26. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ARHGEF26 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ARHGEF26-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.